Publications by authors named "A Cagigi"
Orthoflavivirus zikaense (Zika) vaccines: What are we waiting for?
Int J Antimicrob Agents
December 2024
Article Synopsis
- - Vaccine priming using germline-targeting immunogens could enhance the development of precision vaccines for serious human diseases, as shown in a clinical trial of eOD-GT8 60mer.
- - The trial found that participants receiving a higher vaccine dose had more VRC01-class bnAb-precursor B cells compared to those receiving a lower dose, but the differences were primarily linked to their IGHV1-2 genotypes.
- - The study highlights the importance of understanding genetic variations in immune response (specifically immunoglobulin alleles) when creating and testing new vaccines in clinical settings.
The immune responses to Novavax's licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-M adjuvanted vaccines predominantly elicits immune events in local tissues with little spillover to the periphery. A third dose of an updated vaccine based on the Gamma (P.
View Article and Find Full Text PDFArticle Synopsis
- The engineered HIV gp120 outer domain germline-targeting version 8 (eOD-GT8) aims to activate naive B cell precursors that can produce VRC01-class antibodies, which are important for HIV protection.
- While research on eOD-GT8's effects has focused on U.S. populations, this study investigates its recognition by naive B cells in sub-Saharan Africa, where HIV prevalence is much higher.
- The findings reveal that individuals in sub-Saharan Africa either have a similar or higher frequency of naive B cells that can recognize eOD-GT8 compared to those in the U.S., suggesting that eOD-GT8 vaccination there could effectively boost CD4bs-directed memory B cell production.
Introduction: After receiving emergency approval during the COVID-19 pandemic, mRNA vaccines have taken center stage in the quest to enhance future vaccination strategies for both infectious diseases and cancer. Indeed, they have significantly overshadowed another facet of genetic vaccination, specifically DNA vaccines. Nevertheless, it is important to acknowledge that both types of genetic vaccines have distinct advantages and disadvantages that set them apart from each other.
View Article and Find Full Text PDF